Press Releases

LOVELAND, Colo., July 17, 2019 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska's President & Chief Executive Officer, will present at the 2019 Canaccord Genuity Annual Growth Conference on

SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US.

ATLANTA, July 17, 2019 /PRNewswire/ -- Eagle Telemedicine announced today that its Chief Medical Officer, Jayne Lee, MD, received the Founder's Award for Telehealth Excellence at InTouch Health's 13th Telehealth Innovation Forum in Santa Barbara, Calif.One of the world's most experien

PHOENIX, July 17, 2019 /PRNewswire/ -- RFID Journal Live! announced Adventist Health White Memorial (AHWM) of Los Angeles as a 2019 winner of the

PHILADELPHIA, July 17, 2019 /PRNewswire/ -- Advocates, supporters, community leaders and healthcare providers join PCOS Challenge: The N

ABBOTT PARK, Ill., July 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019.Second-quarter worldwide sales of $8.0 billion increased 2.7 percent on a reported basis and 7.5 percent on an organic* basis. Reported diluted EPS from continuin

DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost SR if approved would be the first-in-class susta

AUSTIN, Texas, July 17, 2019 /PRNewswire/ -- Elios Therapeutics, a biopharmaceutical company developing innovative autologous, particle-delivered, dendritic cell cancer vaccines, today announced positive top-line results from the Company's prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its lead immuno-oncology candidate, th

VANCOUVER, British Columbia, July 17, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTCBB: MYMMF) ("MYM" or "The Company") announces it has closed the second tranche of its non-brokered private placement announced on July 5, 2019 of 2,528,174 units at a price of $0.324 for gr

VANCOUVER, July 17, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), is pleased to announce that, pursuant a convertible debenture issued to Choom by Coastal Green Holdings Ltd., Choom will, on conversion of the debenture, acquire a 19.9% equity interest in Coastal Green.